Morning Briefing
Summaries of health policy coverage from major news organizations
Independent Doctors Decry Shift To Private-Equity Firm, But Aren't Sure What To Do Next
Emergency medicine physicians under contract with Valley Health in Winchester, Virginia, said they were blindsided by the news that the health system planned to end their contract and partner with a private-equity owned practice management company instead. "You're always taught as a young kid, you got to stand up for your rights," said Ronak Shah, MD, vice president of Emergency Medicine of Blue Ridge (EMBR), an independent, physician-led company. Those ideals, however, crashed headlong into harsh realities -- from the cost of litigation to the lack of strong legal protections for independent practice physicians in Virginia. (Firth, 6/15)
A new study suggests that post-COVID-19 condition (PCC), commonly known as long COVID, has placed a substantial burden on healthcare systems in the years since the onset of the pandemic and is associated with significantly higher healthcare use and costs compared with either COVID infection without lingering symptoms or no history of infection. (Bergeson, 6/15)
Buchanan General Hospital paid for the children of two of its top executives to become doctors through a program that was designed to provide loans for medical training, such as medical school or nursing school. However, the payments are listed as grants, not loans, on the nonprofit hospital鈥檚 tax filings, and the hospital has declined to answer questions about the discrepancy or say whether others received similar benefits. (Schabacker, 6/16)
Acquiring four hospitals in southwest Michigan was not an easy path for Beacon Health System. The nonprofit system, headquartered in South Bend, Indiana, is nearly a year into post-deal integration after purchasing facilities from Ascension last July 鈥 the largest acquisition in its history. It added more than 2,700 employees across the hospitals, 35 outpatient clinics and an ambulatory surgery center. (Hudson, 6/15)
More from the insurance, tech, and pharmaceutical sectors 鈥
Centene will offer buyouts to employees as it navigates a significant membership decline, a spokesperson confirmed to Fierce Healthcare. The spokesperson said that on Monday the insurer announced a voluntary separation program designed to "to support employees who may be considering a transition." It's unclear how many people Centene is aims to reach with the program, but Centene employs about 61,000 people in total. (Minemyer, 6/15)
Nonprofit Blue Cross and Blue Shield health insurers underperformed relative to national and regional competitors last year as costs mounted. Only seven nonprofit Blues plans reported positive operating margins in 2025, one fewer than the prior year, according to an S&P Global Market Intelligence analysis of health insurance company regulatory filings. (Tepper, 6/15)
A decade since its founding, the International Human Cell Atlas Consortium is hosting a high-profile meeting in Boston this week, with panels featuring more than two dozen prominent academics and biotech industry leaders, including Genentech鈥檚 Aviv Regev, David Altshuler of Vertex Pharmaceuticals, and Eric Lander from the Broad Institute. The event, which is expected to draw hundreds of scientists from across the globe, comes at an inflection point in the HCA鈥檚 ambitious aim to build a comprehensive reference map of all the different types of cells that make up a human body.聽(Molteni, 6/16)
Masimo Corp. CEO Katie Szyman posted on social media she is stepping down following the company鈥檚 acquisition by Danaher Corp. Szyman, who was appointed to lead Masimo in February 2025, in a Sunday LinkedIn post announced her decision to leave the patient monitoring company. Life sciences company Danaher announced Wednesday it completed its acquisition of Masimo. The $9.9 billion deal made Masimo a wholly owned subsidiary of Danaher, and its common stock is no longer trading on the Nasdaq Stock Market. (Dubinsky, 6/15)
Sigma Healthcare Ltd. announced its withdrawal from the Boots sale process, after being among the parties exploring a potential acquisition of the British pharmacy chain in a deal that could be worth as much as $10 billion. Sigma 鈥渉as elected to withdraw its interest and cease discussions immediately,鈥 it said in a statement Monday. (Leigh, 6/15)